Kodiak Sciences to Report Phase 3 Daybreak Study Results on September 28
1 report, 1 independent
Updated Sep 25
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kodiak Sciences announced that it will report topline results from the Daybreak study on Monday, September 28, 2026. The Phase 3 study evaluated two products, Zenkuda and KSI-501, for the treatment of patients with wet age-related macular degeneration. Kodiak Sciences also stated that it is forecasting the availability of relevant data from PEAK in 2026 or 2027.
From prnewswire.com
Why it matters
The results from the Daybreak study are critical for Kodiak Sciences as a company focused on developing late-stage clinical programs. The outcome of the evaluation of Zenkuda and KSI-501 could influence the company's future commercialization plans and partnerships.
From prnewswire.com
Who's involved
- Kodiak Sciences Inc.Biotech company conducting the Daybreak Phase 3 study and forecasting future data from PEAK.
- PEAKChemical company whose data is being forecasted by Kodiak Sciences for future analysis.
Keep exploring
The entities involved
-
Kodiak Sciences Inc.
biotech company
-
PEAK
American automotive and chemical company
Nothing else this week.